Reduced myocardial nerve growth factor expression in human and experimental heart failure.
Maintenance of cardiac performance is tightly controlled by the autonomic nervous system. In congestive heart failure (CHF), although the adverse pathophysiological effects of cardiac sympathetic overactivity are increasingly recognized, the paradoxical finding of reduced sympathetic innervation density in the failing heart remains unexplained. Given these observations, we tested the hypothesis that a reduction in the myocardial production of nerve growth factor (NGF), which is important for the maintenance of sympathetic neuronal survival, could explain the conflicting neurochemical and neuroanatomical profile of CHF. In healthy humans (n=11), there was a significantly greater transcardiac venoarterial plasma NGF gradient than in CHF patients (n=11, P<0.05). In a rat model of CHF, a 40% reduction (P<0.05) NGF mRNA expression was apparent in association with a 24% reduction in tissue NGF content (P<0.05). In conjunction, evidence of reduced sympathetic innervation in the failing heart was apparent, as measured histologically by catecholamine fluorescence and by expression of the neuronal NGF receptor trkA. Norepinephrine (10 micromol/L) exposure reduced both NGF mRNA and protein expression in isolated cardiomyocytes, suggesting that myocardial NGF downregulation may represent an adaptive response to sympathetic overactivity. These data indicate that NGF expression in the heart is dynamic and may be altered in cardiovascular disease states. In CHF, reduced NGF expression may account for alterations in sympathetic neuronal function and neuroanatomy. The full text of this article is available at http://www.circresaha.org.
Kaye
D M
DM
Molecular Neurocardiology Laboratory, Baker Medical Research Institute, PO Box 6492, StKilda Rd Central, Melbourne VIC 8008, Australia. david.kaye@baker.edu.au
Vaddadi
G
G
Gruskin
S L
SL
Du
X J
XJ
Esler
M D
MD
D000317:Adrenergic alpha-Antagonists / Q000494:pharmacology; D000328:Adult; D000818:Animals; D002478:Cells, Cultured; D015536:Down-Regulation; D006333:Heart Failure / Q000378:metabolism*; D006801:Humans; D008875:Middle Aged; D009206:Myocardium / Q000378:metabolism*; D020932:Nerve Growth Factor / Q000187:drug effects / Q000235:genetics / Q000378:metabolism*; D009638:Norepinephrine / Q000494:pharmacology; D011224:Prazosin / Q000494:pharmacology; D011493:Protein Kinase C / Q000378:metabolism; D012333:RNA, Messenger / Q000032:analysis; D051381:Rats; D017207:Rats, Sprague-Dawley
D000317:Adrenergic alpha-Antagonists; D012333:RNA, Messenger; D020932:Nerve Growth Factor; D011493:Protein Kinase C; D009638:Norepinephrine; D011224:Prazosin